Top in rheumatology: Humira biosimilars, refractory Lyme arthritis
Amid a lawsuit battle concerning a Humira biosimilar product between AbbVie and Alvotech, experts predict that the market will explode as greater competition begins to erode Humira’s profits.
An in-depth look at the imminent launch of Humira biosimilars was the top story in rheumatology last week.
Another top story was about new findings that suggest refractory Lyme arthritis may persist due to a maladaptive immune response.
Read these and more top stories in rheumatology below:
Market gears up for biosimilar boom in 2023 as Humira exclusivity draws to a close
On May 11, Icelandic-based drug developer Alvotech filed a lawsuit against AbbVie seeking to undo what it alleges is a “minefield” of “invalid” patents surrounding what is arguably the pharma giant’s most prized possession: Humira. Read more.
Refractory Lyme arthritis may be driven by 'maladaptive immune response'
A maladaptive immune response may be prompting arthritic complications in patients with persistent and drug-refractory Lyme disease, according to a speaker at the EULAR 2021 Congress. Read more.
Risk for COVID-19 hospitalization, death 35% higher in patients with RA
A study of patients who received care at Veterans Affairs centers found that rheumatoid arthritis is linked to a 25% higher risk for COVID-19, and a 35% increased risk for related hospitalization and death, according to data. Read more.
FDA rejects IV tramadol as opioid alternative for second time
Avenue Therapeutics announced the FDA has issued a second complete response letter regarding the new drug application for intravenous tramadol as an analgesic treatment for patients with acute pain. Read more.
Infection risk lower with ustekinumab than other biologics, apremilast in PsA, psoriasis
Patients with psoriasis or psoriatic arthritis treated with ustekinumab demonstrated a 1.4- to 3-times lower risk for hospitalization with serious infections than those who received other biologics or apremilast, according to data. Read more.